Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Completed · Phase 1

Conditions studied: Kidney Cancer, Melanoma (Skin)

In brief

RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate the immune system and stop cancer cells from growing. Biological therapy may be an effective treatment for metastatic melanoma and metastatic kidney cancer. PURPOSE: Phase I trial to study the effectiveness of flt3L combined with CD40-ligand in treating patients who have metastatic melanoma or metastatic kidney cancer.

Key facts

Study ID

NCT00020540

Run by

National Cancer Institute (NCI)

Starts

2001-03-01

Last updated by the study team

2015-04-30

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Surgery Branch — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.